1. This paper deals with glucose synthesis inhibitors for the treatment of metabolic diseases, such as monomeric or enzyme storage diseases combined with enzyme replacement therapy； For cancer treatment, claim 1: a compound represented by a structural formula (1) or a salt or derivative thereof acceptable to the drug, wherein n is 1, 2 or 3, M is 0 or 1, P is 0 or 1, t is 0, 1 or 2, y is 1 or 2, Z is 0, 1 or 2, e is s, O, NH, NO2, NCN, NR, nor or N2R； X1 is CR1, when m is 1 or N, when m is 0, X2 is O, NH, CH2,SO2, nh-so2, ch asphalt C1-6 o-nr2； X3 is O, NH, CH2,CO, -CH-C1-6 alkyl, SO2NH, -CO-NH- or -NR3； X4 is CR4R5, CH2CR4R5 or CH2-C1-6 alkyl-CR4R5； X5 is a direct bond, O, S, SO2, CR4R5, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkenyl, C1-6 alkenyloxy； R is C6-12 aryl, C2-9 heteroaryl, C1-6 alkyl, C2-9 heteroarylC1-6 alkyl； R1 is H, CN, C1-6 alkylcarbonyl or C1-6 alkyl； R2 and R3 are each independently -H, C1-6 alkyl optionally substituted by one or more substituents selected from the group consisting of halogen, C1-6 alkyl, C6-12 aryl, C2-9 heteroaryl, C1-6 alkylC6 alkyl- 12, C6-12 halo-aryl, and C2-9 halo-heteroaryl, or optionally when X2 is -NR2 and X3 is -NR3,R2 and R3 can be combined with nitrogen atoms to form a non aromatic heterocyclic ring, which is replaced by one or more selected halogen substitutes, C1-6 tar, arilo C6-12, heteromorphic c2-9, c1-6arilo C6-12, halo arilo C6-12 and halo hetero c2-9； R4 and R5 are independently selected from h, C1-6 tar, or the carbon connected with them forms a cyclopentanediol c3-10 or cyclopentane c3-10； R6 es-h, halogen-cn, arilo C6-12, ariloxi C6-12, c1xi-6； C1-6 tar is replaced by 1-4 halogen or C1-6 tar； A1 is No. c2-6 asphalt；Cycloquilo c3-10, arilo C6-12, heterosexual c2-9, heterosexual c2-9 or benzo heterosexual cycloquilo c2-9, optionally replaced by one or more halo substitutes, C1-6 tar optionally replaced by one to three halogens, C1-6 tar, ammonia, rental C1-6, C1-6, diallamino C1-6, alcox C1-6, nitro, Cn, - Oh, C1-6
